Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor, Subjects”

5,749 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 5,749 results

Very early researchStudy completedNCT05643248
What this trial is testing

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

Who this might be right for
Multiple Myeloma
Nanexa AB 9
Early research (Phase 1)Study completedNCT00697632
What this trial is testing

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Who this might be right for
Advanced Cancer
Mirati Therapeutics Inc. 180
Early research (Phase 1)Study completedNCT01629758
What this trial is testing

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Who this might be right for
Neoplasms by Site
Bristol-Myers Squibb 33
Early research (Phase 1)Study completedNCT01138033
What this trial is testing

Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 74
Large-scale testing (Phase 3)Ended earlyNCT03400943
What this trial is testing

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Who this might be right for
Uterine Fibroids
Bayer 93
Testing effectiveness (Phase 2)Ended earlyNCT01090414
What this trial is testing

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Who this might be right for
Chronic Lymphocytic LeukemiaLymphoma, Non-Hodgkin
Gilead Sciences 202
Testing effectiveness (Phase 2)Study completedNCT00101816
What this trial is testing

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Who this might be right for
Chronic Myeloid LeukemiaBlast Crisis
Bristol-Myers Squibb 124
Early research (Phase 1)Ended earlyNCT03220347
What this trial is testing

Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinNeoplasms
Celgene 139
Early research (Phase 1)Study completedNCT02723955
What this trial is testing

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Who this might be right for
Neoplasms
GlaxoSmithKline 829
Testing effectiveness (Phase 2)WithdrawnNCT04408898
What this trial is testing

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
Adaptimmune
Large-scale testing (Phase 3)Study completedNCT02872116
What this trial is testing

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction CancerEsophageal Adenocarcinoma
Bristol-Myers Squibb 2,031
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Testing effectiveness (Phase 2)Study completedNCT00020735
What this trial is testing

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

Who this might be right for
Prostate Cancer
Joel Nelson, MD 45
Testing effectiveness (Phase 2)Looking for participantsNCT05286814
What this trial is testing

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Who this might be right for
Metastatic Colorectal Cancer (Mcrc)Intrahepatic Cholangiocarcinoma (Icc)Intrahepatic Bile Duct Cancer+10 more
National Cancer Institute (NCI) 70
Early research (Phase 1)Study completedNCT02063204
What this trial is testing

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

Who this might be right for
Solid Tumours
AstraZeneca 24
Early research (Phase 1)Study completedNCT01061749
What this trial is testing

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Who this might be right for
Adult Solid Neoplasm
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT06326411
What this trial is testing

Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Who this might be right for
OncologyMEK MutationRAF Gene Mutation+6 more
Nested Therapeutics, Inc 230
Large-scale testing (Phase 3)Study completedNCT00117598
What this trial is testing

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Who this might be right for
Lymphoma
Pfizer 169
Early research (Phase 1)Ended earlyNCT04249947
What this trial is testing

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Who this might be right for
Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, Prostate+14 more
Poseida Therapeutics, Inc. 40
Testing effectiveness (Phase 2)Ended earlyNCT06516926
What this trial is testing

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Who this might be right for
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 11
Next Page